Onivyde discount program?

See the DrugPatentWatch profile for Onivyde

Information on discount programs for Onivyde is not readily available in the provided context.

What is Onivyde?

Onivyde (nal-IRI) is a liposomal encapsulation of irinotecan, used in combination with fluorouracil and leucovorin to treat patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based chemotherapy [1].

How does Onivyde work?

Onivyde is a topoisomerase I inhibitor. The liposomal encapsulation aims to alter the distribution and delivery of irinotecan. By encapsulating irinotecan in liposomes, the drug is intended to accumulate in tumors and release its active component over time [1].

Who manufactures Onivyde?

Ipsen Biopharmaceuticals, Inc. is the manufacturer of Onivyde [1].

When did Onivyde receive FDA approval?

The U.S. Food and Drug Administration (FDA) approved Onivyde for its indicated use in October 2015 [1].